Patient–provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study

Jivan Achar,Alan J. Budney,Cara A. Struble
DOI: https://doi.org/10.1111/ajad.13656
2024-10-26
American Journal on Addictions
Abstract:Background and Objectives Limited evidence guides the efficacy and safety of cannabis for therapeutic purposes (CTP). Healthcare providers lack requisite knowledge to advise and support patients. This study aimed to describe and compare several aspects of initial CTP interactions across different provider types. Methods Adult cannabis consumers (N = 507) from the United States completed an anonymous online survey about their initial CTP interaction with their healthcare provider. Providers were categorized into four groups (Mental Health [MH], Family Medicine [FM], Medical Clinics [MC], and Other Specialty [OS]). Analyses compared several aspects of the interaction (e.g., risk mitigation, recommendations, satisfaction/confidence) across groups. Results Less than half of the sample reported discussion of cannabis risks (44.0%) or follow‐ups at subsequent visits (46.7%). Recommendations (where to obtain, consumption method, dose, frequency, and authorization) were uncommon (9.7%–25.2%). While the MH group reported the highest rates of risk mitigation behaviors, regression models adjusted for sociodemographic and cannabis characteristics were largely nonsignificant. For recommendations, the MC group was more likely than the MH group to report receiving all recommendations (p
substance abuse
What problem does this paper attempt to address?